Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease

BackgroundBile acids are vital regulators of liver metabolism, and their dysregulation is closely linked with the progression of nonalcoholic fatty liver disease (NAFLD). Profiling these bile acids may provide valuable diagnostic and prognostic markers for these conditions. This study aimed to evalu...

Full description

Saved in:
Bibliographic Details
Published in:Egyptian Liver Journal 2024-10, Vol.14 (1), p.70-16
Main Authors: Basuni, Ashraf Abbass, Sweed, Dina, Elgazzar, Mohammed Fathey, Khalil, Ashraf
Format: Article
Language:English
Subjects:
Acids
Bile
Bile acids
Biomarkers
Biopsy
Cholesterol
Gallbladder diseases
Homeostasis
Inflammation
Insulin
Laboratories
Lipids
Liquid chromatography-mass spectrometry
Liver cirrhosis
Liver diseases
Metabolism
NAFLD
NASH
Nonalcoholic fatty liver disease
Nonalcoholic steatohepatitis
Pathogenesis
Ultrasonic imaging
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 16
container_issue 1
container_start_page 70
container_title Egyptian Liver Journal
container_volume 14
creator Basuni, Ashraf Abbass
Sweed, Dina
Elgazzar, Mohammed Fathey
Khalil, Ashraf
description BackgroundBile acids are vital regulators of liver metabolism, and their dysregulation is closely linked with the progression of nonalcoholic fatty liver disease (NAFLD). Profiling these bile acids may provide valuable diagnostic and prognostic markers for these conditions. This study aimed to evaluate bile acid profiles in NAFLD patients and assess their potential as biomarkers for diagnosing and predicting disease progression. Serum levels of 14 bile acids were measured in 25 normal healthy controls (NHC), 35patients with metabolic dysfunction–associated steatotic liver disease (MASLD), and 40 patients with NASH, categorized by the NAFLD Activity Score (NAS). Quantification was performed using high-performance liquid chromatography-tandem mass spectrometry (HPLC–MS/MS).ResultsPrimary unconjugated bile acids, CA and CDCA, along with conjugated acids GCA, GCDCA, TCA, and TCDCA, were significantly elevated in both MASLD and NASH compared to NHC (all p 
doi_str_mv 10.1186/s43066-024-00378-9
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_proquest_journals_3114647947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9a5195c162824527a313805c8eb327d7</doaj_id><sourcerecordid>3114647947</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-9383f542bf5e26ee32bb33ba52fd784f8885dfe8cb74c10dbc199c860506e9353</originalsourceid><addsrcrecordid>eNo9j01LAzEQhoMoWGr_gKeA59V8fxyl1A8oeNHzkmSTmppu1mRb7L93teJcZnjn4WEGgGuMbjFW4q4yioRoEGENQlSqRp-BGUEaNYIQcf4_Y3UJFrVu0VQKywmdAbf6GlIusd_A6st-B21MHhoXuwpNhUMefT9Gk2Cf-9gfTI0HPzF5Z8qHLxWGXH5WJrn8nlN0MJhxPMI0YQV2sXpT_RW4CCZVv_jrc_D2sHpdPjXrl8fn5f26cRSjsdFU0cAZsYF7IrynxFpKreEkdFKxoJTiXfDKWckcRp11WGunBOJIeE05nYPnk7fLZtsOJU5HHttsYvsb5LJpTRmjS77VhmPNHRZEEcaJNBRThbhT3lIiOzm5bk6uoeTPva9ju837Mv1ZW4oxE0xqJuk3r4ByIQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3114647947</pqid></control><display><type>article</type><title>Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease</title><source>Publicly Available Content Database</source><source>Springer Nature - SpringerLink Journals - Fully Open Access </source><creator>Basuni, Ashraf Abbass ; Sweed, Dina ; Elgazzar, Mohammed Fathey ; Khalil, Ashraf</creator><creatorcontrib>Basuni, Ashraf Abbass ; Sweed, Dina ; Elgazzar, Mohammed Fathey ; Khalil, Ashraf</creatorcontrib><description>BackgroundBile acids are vital regulators of liver metabolism, and their dysregulation is closely linked with the progression of nonalcoholic fatty liver disease (NAFLD). Profiling these bile acids may provide valuable diagnostic and prognostic markers for these conditions. This study aimed to evaluate bile acid profiles in NAFLD patients and assess their potential as biomarkers for diagnosing and predicting disease progression. Serum levels of 14 bile acids were measured in 25 normal healthy controls (NHC), 35patients with metabolic dysfunction–associated steatotic liver disease (MASLD), and 40 patients with NASH, categorized by the NAFLD Activity Score (NAS). Quantification was performed using high-performance liquid chromatography-tandem mass spectrometry (HPLC–MS/MS).ResultsPrimary unconjugated bile acids, CA and CDCA, along with conjugated acids GCA, GCDCA, TCA, and TCDCA, were significantly elevated in both MASLD and NASH compared to NHC (all p &lt; 0.05). While levels increased progressively from NHC to MASLD to NASH, no significant differences were observed between MASLD and NASH except for GCA and TCA (P &lt; 0.05). Similarly, secondary bile acids LCA, TLCA, GUDCA, and TUDCA were higher in MASLD and NASH compared to NHC (all p &lt; 0.05).Logistic regression identified CA (odds ratio = 2.05, p = 0.02), CDCA (odds ratio = 1.58, p = 0.04), GCA (odds ratio = 1.92, p = 0.03) and DCA (odds ratio = 2.06, p = 0.04) as significant predictors of fibrosis. For active inflammation, GCA (odds ratio = 2.04, p = 0.04), and TCA (odds ratio = 1.94, p = 0.04) were significant predictors. In steatosis, CA, CDCA, GCA, DCA, TDCA, TLCA, and UDCA were notable predictors, with high odds ratios.ConclusionThe study highlights significant alterations in bile acid profiles associated with NAFLD progression. Specific bile acids, such as CA, GCA, TCA, and TCDCA are strong predictors of disease severity, indicating their potential as biomarkers for NAFLD treatment and prognosis.</description><identifier>ISSN: 2090-6218</identifier><identifier>EISSN: 2090-6226</identifier><identifier>DOI: 10.1186/s43066-024-00378-9</identifier><language>eng</language><publisher>Menoufiya: Springer Nature B.V</publisher><subject>Acids ; Bile ; Bile acids ; Biomarkers ; Biopsy ; Cholesterol ; Gallbladder diseases ; Homeostasis ; Inflammation ; Insulin ; Laboratories ; Lipids ; Liquid chromatography-mass spectrometry ; Liver cirrhosis ; Liver diseases ; Metabolism ; NAFLD ; NASH ; Nonalcoholic fatty liver disease ; Nonalcoholic steatohepatitis ; Pathogenesis ; Ultrasonic imaging</subject><ispartof>Egyptian Liver Journal, 2024-10, Vol.14 (1), p.70-16</ispartof><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3114647947/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3114647947?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,75126</link.rule.ids></links><search><creatorcontrib>Basuni, Ashraf Abbass</creatorcontrib><creatorcontrib>Sweed, Dina</creatorcontrib><creatorcontrib>Elgazzar, Mohammed Fathey</creatorcontrib><creatorcontrib>Khalil, Ashraf</creatorcontrib><title>Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease</title><title>Egyptian Liver Journal</title><description>BackgroundBile acids are vital regulators of liver metabolism, and their dysregulation is closely linked with the progression of nonalcoholic fatty liver disease (NAFLD). Profiling these bile acids may provide valuable diagnostic and prognostic markers for these conditions. This study aimed to evaluate bile acid profiles in NAFLD patients and assess their potential as biomarkers for diagnosing and predicting disease progression. Serum levels of 14 bile acids were measured in 25 normal healthy controls (NHC), 35patients with metabolic dysfunction–associated steatotic liver disease (MASLD), and 40 patients with NASH, categorized by the NAFLD Activity Score (NAS). Quantification was performed using high-performance liquid chromatography-tandem mass spectrometry (HPLC–MS/MS).ResultsPrimary unconjugated bile acids, CA and CDCA, along with conjugated acids GCA, GCDCA, TCA, and TCDCA, were significantly elevated in both MASLD and NASH compared to NHC (all p &lt; 0.05). While levels increased progressively from NHC to MASLD to NASH, no significant differences were observed between MASLD and NASH except for GCA and TCA (P &lt; 0.05). Similarly, secondary bile acids LCA, TLCA, GUDCA, and TUDCA were higher in MASLD and NASH compared to NHC (all p &lt; 0.05).Logistic regression identified CA (odds ratio = 2.05, p = 0.02), CDCA (odds ratio = 1.58, p = 0.04), GCA (odds ratio = 1.92, p = 0.03) and DCA (odds ratio = 2.06, p = 0.04) as significant predictors of fibrosis. For active inflammation, GCA (odds ratio = 2.04, p = 0.04), and TCA (odds ratio = 1.94, p = 0.04) were significant predictors. In steatosis, CA, CDCA, GCA, DCA, TDCA, TLCA, and UDCA were notable predictors, with high odds ratios.ConclusionThe study highlights significant alterations in bile acid profiles associated with NAFLD progression. Specific bile acids, such as CA, GCA, TCA, and TCDCA are strong predictors of disease severity, indicating their potential as biomarkers for NAFLD treatment and prognosis.</description><subject>Acids</subject><subject>Bile</subject><subject>Bile acids</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Cholesterol</subject><subject>Gallbladder diseases</subject><subject>Homeostasis</subject><subject>Inflammation</subject><subject>Insulin</subject><subject>Laboratories</subject><subject>Lipids</subject><subject>Liquid chromatography-mass spectrometry</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Metabolism</subject><subject>NAFLD</subject><subject>NASH</subject><subject>Nonalcoholic fatty liver disease</subject><subject>Nonalcoholic steatohepatitis</subject><subject>Pathogenesis</subject><subject>Ultrasonic imaging</subject><issn>2090-6218</issn><issn>2090-6226</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNo9j01LAzEQhoMoWGr_gKeA59V8fxyl1A8oeNHzkmSTmppu1mRb7L93teJcZnjn4WEGgGuMbjFW4q4yioRoEGENQlSqRp-BGUEaNYIQcf4_Y3UJFrVu0VQKywmdAbf6GlIusd_A6st-B21MHhoXuwpNhUMefT9Gk2Cf-9gfTI0HPzF5Z8qHLxWGXH5WJrn8nlN0MJhxPMI0YQV2sXpT_RW4CCZVv_jrc_D2sHpdPjXrl8fn5f26cRSjsdFU0cAZsYF7IrynxFpKreEkdFKxoJTiXfDKWckcRp11WGunBOJIeE05nYPnk7fLZtsOJU5HHttsYvsb5LJpTRmjS77VhmPNHRZEEcaJNBRThbhT3lIiOzm5bk6uoeTPva9ju837Mv1ZW4oxE0xqJuk3r4ByIQ</recordid><startdate>20241009</startdate><enddate>20241009</enddate><creator>Basuni, Ashraf Abbass</creator><creator>Sweed, Dina</creator><creator>Elgazzar, Mohammed Fathey</creator><creator>Khalil, Ashraf</creator><general>Springer Nature B.V</general><general>SpringerOpen</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope></search><sort><creationdate>20241009</creationdate><title>Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease</title><author>Basuni, Ashraf Abbass ; Sweed, Dina ; Elgazzar, Mohammed Fathey ; Khalil, Ashraf</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-9383f542bf5e26ee32bb33ba52fd784f8885dfe8cb74c10dbc199c860506e9353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acids</topic><topic>Bile</topic><topic>Bile acids</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Cholesterol</topic><topic>Gallbladder diseases</topic><topic>Homeostasis</topic><topic>Inflammation</topic><topic>Insulin</topic><topic>Laboratories</topic><topic>Lipids</topic><topic>Liquid chromatography-mass spectrometry</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Metabolism</topic><topic>NAFLD</topic><topic>NASH</topic><topic>Nonalcoholic fatty liver disease</topic><topic>Nonalcoholic steatohepatitis</topic><topic>Pathogenesis</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Basuni, Ashraf Abbass</creatorcontrib><creatorcontrib>Sweed, Dina</creatorcontrib><creatorcontrib>Elgazzar, Mohammed Fathey</creatorcontrib><creatorcontrib>Khalil, Ashraf</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Egyptian Liver Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Basuni, Ashraf Abbass</au><au>Sweed, Dina</au><au>Elgazzar, Mohammed Fathey</au><au>Khalil, Ashraf</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease</atitle><jtitle>Egyptian Liver Journal</jtitle><date>2024-10-09</date><risdate>2024</risdate><volume>14</volume><issue>1</issue><spage>70</spage><epage>16</epage><pages>70-16</pages><issn>2090-6218</issn><eissn>2090-6226</eissn><abstract>BackgroundBile acids are vital regulators of liver metabolism, and their dysregulation is closely linked with the progression of nonalcoholic fatty liver disease (NAFLD). Profiling these bile acids may provide valuable diagnostic and prognostic markers for these conditions. This study aimed to evaluate bile acid profiles in NAFLD patients and assess their potential as biomarkers for diagnosing and predicting disease progression. Serum levels of 14 bile acids were measured in 25 normal healthy controls (NHC), 35patients with metabolic dysfunction–associated steatotic liver disease (MASLD), and 40 patients with NASH, categorized by the NAFLD Activity Score (NAS). Quantification was performed using high-performance liquid chromatography-tandem mass spectrometry (HPLC–MS/MS).ResultsPrimary unconjugated bile acids, CA and CDCA, along with conjugated acids GCA, GCDCA, TCA, and TCDCA, were significantly elevated in both MASLD and NASH compared to NHC (all p &lt; 0.05). While levels increased progressively from NHC to MASLD to NASH, no significant differences were observed between MASLD and NASH except for GCA and TCA (P &lt; 0.05). Similarly, secondary bile acids LCA, TLCA, GUDCA, and TUDCA were higher in MASLD and NASH compared to NHC (all p &lt; 0.05).Logistic regression identified CA (odds ratio = 2.05, p = 0.02), CDCA (odds ratio = 1.58, p = 0.04), GCA (odds ratio = 1.92, p = 0.03) and DCA (odds ratio = 2.06, p = 0.04) as significant predictors of fibrosis. For active inflammation, GCA (odds ratio = 2.04, p = 0.04), and TCA (odds ratio = 1.94, p = 0.04) were significant predictors. In steatosis, CA, CDCA, GCA, DCA, TDCA, TLCA, and UDCA were notable predictors, with high odds ratios.ConclusionThe study highlights significant alterations in bile acid profiles associated with NAFLD progression. Specific bile acids, such as CA, GCA, TCA, and TCDCA are strong predictors of disease severity, indicating their potential as biomarkers for NAFLD treatment and prognosis.</abstract><cop>Menoufiya</cop><pub>Springer Nature B.V</pub><doi>10.1186/s43066-024-00378-9</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-6218
ispartof Egyptian Liver Journal, 2024-10, Vol.14 (1), p.70-16
issn 2090-6218
2090-6226
language eng
recordid cdi_proquest_journals_3114647947
source Publicly Available Content Database; Springer Nature - SpringerLink Journals - Fully Open Access
subjects Acids
Bile
Bile acids
Biomarkers
Biopsy
Cholesterol
Gallbladder diseases
Homeostasis
Inflammation
Insulin
Laboratories
Lipids
Liquid chromatography-mass spectrometry
Liver cirrhosis
Liver diseases
Metabolism
NAFLD
NASH
Nonalcoholic fatty liver disease
Nonalcoholic steatohepatitis
Pathogenesis
Ultrasonic imaging
title Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A48%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploring%20serum%20bile%20acids%20as%20potential%20noninvasive%20biomarkers%20for%20nonalcoholic%20fatty%20liver%20disease&rft.jtitle=Egyptian%20Liver%20Journal&rft.au=Basuni,%20Ashraf%20Abbass&rft.date=2024-10-09&rft.volume=14&rft.issue=1&rft.spage=70&rft.epage=16&rft.pages=70-16&rft.issn=2090-6218&rft.eissn=2090-6226&rft_id=info:doi/10.1186/s43066-024-00378-9&rft_dat=%3Cproquest_doaj_%3E3114647947%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c310t-9383f542bf5e26ee32bb33ba52fd784f8885dfe8cb74c10dbc199c860506e9353%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3114647947&rft_id=info:pmid/&rfr_iscdi=true